https://www.selleckchem.com/pr....oducts/Gefitinib.htm
This rapid, simple and sensitive RT-LAMP method paves a way for a large screening at public domain and hospitals, particularly regional hospitals and medical centres in rural areas. © 2020 The Authors. Microbial Biotechnology published by John Wiley Sons Ltd and Society for Applied Microbiology.BACKGROUND Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2-mutated non-small cell
Aimer
Commentaire
Partagez
